MindMed continues to raise capital. This time issuing 11,364,000 units at CAD$4.40 for gross proceeds of CAD$50,001,600.
Articles
Eleusis Launches Clinical Development of Psychedelic Infusion Therapies for Major Depressive Disorder and Acquires Kalypso Wellness Centers
Eleusis acquires a ketamine therapy provider and announces a new R&D program.
MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy
MindMed announces a successful pre-Investigational New Drug meeting with the FDA regarding its Project Lucy (LSD) research for anxiety.
UK Approves Trials Testing DMT as Depression Treatment
The United Kingdom has approved trials by London-based Small Pharma for assessing the safety, and later efficacy, of N,N-dimethyltryptamine – or DMT – for depression, according to a Pharm Exec report. It is the world’s first clinical trial for studying DMT as a depression treatment.
Arizona Releases Draft Marijuana Regulations To Implement Legalization Vote
One month after Arizona voters overwhelmingly approved a ballot initiative to legalize marijuana for adult use, regulators have already put forward draft regulations to implement the program.
MindMed Closes Upsized Financing of CAD $34.5m, Gross Proceeds Raised Since Company Founding Now Total CAD $121.4m (USD $94.8m)
MindMed's recent financing has closed after being upsized all the way to CAD$34.5 million.
Psychedelic Stocks Pump Up The Volume
Psychedelic stocks are hitting new highs -- and doing so on record trading volumes. Feeding frenzies.
Magic Mushrooms Are Expanding Minds and Advancing an Emerging Field of Science
They’ve been credited in part for the musical and artistic revolutions of the late 1960s. According to some scientific opinions, they have potentially inspired early creativity in humans and our ancient ancestors.
Rotation Opportunity As Three Top Psychedelic Stocks Explode
Leading psychedelic stocks have gone ballistic in recent weeks. But where will investors find the NEXT multi-bagger opportunity?
Mind Cure (CSE: MCUR | OTC: MCURF) Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
The company is set to open a therapeutic health and training center in Kelowna, British Columbia in May of 2021
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants
Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.
Champignon Brands Appoints Christopher Hobbs as Interim Chief Financial Officer
Champignon Brands names an interim CFO after Stephen Brohman resigns.
Aurora, Colorado Officials May Soon Allow Cannabis Delivery
Marijuana delivery may soon be arriving in Aurora, Colorado.
Seven In Ten Americans Back Expunging Marijuana Convictions, New Poll Finds
Seven in ten Americans support clearing the records of people with non-violent marijuana convictions, according to a new poll.
Anchorage recreational marijuana sales a bullish indicator of Alaska’s growing market
Recreational marijuana sales in Alaska’s largest city continued to grow in 2020 despite the COVID-19 pandemic, highlighting the resiliency of the state’s adult-use industry even in challenging conditions.